Roche in Novo Nordisk takeover rumour  

Having acquired insulin pump maker Disetronic, Roche is rumoured to be preparing a bid for diabetes care giant Novo Nordisk

Rumours are circulating that Swiss pharmaceutical giant Roche is contemplating a bid for Denmark’s largest medical group Novo Nordisk – one of the two companies that dominate the global diabetes market. Speculation about a possible bid is fuelled by the fact that Roche recently acquired Disetronic, the world’s second biggest manufacturer of insulin pumps, at a cost of approximately DKK 8.4 billion (USD 1.2 billion). Co-Managing Director in the holding company Novo A/S Henrik Gürtler says that no offer has been received from Roche.


Novo A/S, which is 100% owned by the Novo Nordisk Foundation, has 27% of the share capital in Novo Nordisk and approximately 70% vote share. The Danish Labour Market Supplementary Pension Fund (ATP) is the second largest shareholder with almost 7% (around 3% of the votes) while Capital Group was recently revealed as the third largest shareholder with 5.01% of the share capital (around 2% of the votes). The news is published in national newspaper Jyllands-Posten.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×